These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

116 related articles for article (PubMed ID: 8888364)

  • 1. Predicting haloperidol treatment response in chronic schizophrenia.
    van Kammen DP; Kelley ME; Yao JK; Gilbertson MW; Gurklis JA; Inosaka T; Saito H; Peters JL; Sato M
    Psychiatry Res; 1996 Aug; 64(1):47-58. PubMed ID: 8888364
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Norepinephrine in acute exacerbations of chronic schizophrenia. Negative symptoms revisited.
    van Kammen DP; Peters J; Yao J; van Kammen WB; Neylan T; Shaw D; Linnoila M
    Arch Gen Psychiatry; 1990 Feb; 47(2):161-8. PubMed ID: 1689140
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Haloperidol response and plasma catecholamines and their metabolites.
    Green AI; Alam MY; Boshes RA; Waternaux C; Pappalardo KM; Fitzgibbon ME; Tsuang MT; Schildkraut JJ
    Schizophr Res; 1993 Jun; 10(1):33-7. PubMed ID: 8369230
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Plasma homovanillic acid as a predictor of response to neuroleptics.
    Davila R; Manero E; Zumarraga M; Andia I; Schweitzer JW; Friedhoff AJ
    Arch Gen Psychiatry; 1988 Jun; 45(6):564-7. PubMed ID: 3377643
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Plasma catecholamine metabolites in schizophrenics: evidence for the two-subtype concept.
    Chang WH; Chen TY; Lin SK; Lung FW; Lin WL; Hu WH; Yeh EK
    Biol Psychiatry; 1990 Mar; 27(5):510-8. PubMed ID: 2310806
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Neuroleptic treatment, symptoms of schizophrenia, and plasma homovanillic acid concentrations revisited.
    Volavka J; Douyon R; Convit A; Czobor P; Cooper TB
    Arch Gen Psychiatry; 1992 Dec; 49(12):999-1000. PubMed ID: 1449388
    [No Abstract]   [Full Text] [Related]  

  • 7. Effects of neuroleptic treatment on symptoms of schizophrenia and plasma homovanillic acid concentrations.
    Davidson M; Kahn RS; Knott P; Kaminsky R; Cooper M; DuMont K; Apter S; Davis KL
    Arch Gen Psychiatry; 1991 Oct; 48(10):910-3. PubMed ID: 1929760
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Psychotogenic drug use and neuroleptic response.
    Bowers MB; Mazure CM; Nelson JC; Jatlow PI
    Schizophr Bull; 1990; 16(1):81-5. PubMed ID: 1970670
    [TBL] [Abstract][Full Text] [Related]  

  • 9. CSF norepinephrine in schizophrenia is elevated prior to relapse after haloperidol withdrawal.
    van Kammen DP; Peters J; van Kammen WB; Nugent A; Goetz KL; Yao J; Linnoila M
    Biol Psychiatry; 1989 Jun; 26(2):176-88. PubMed ID: 2472177
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Plasma catecholamine metabolites as markers for psychosis and antipsychotic response in schizophrenia.
    Kelley ME; Yao JK; van Kammen DP
    Neuropsychopharmacology; 1999 Jun; 20(6):603-11. PubMed ID: 10327429
    [TBL] [Abstract][Full Text] [Related]  

  • 11. First-episode neuroleptic-free schizophrenics: concentrations of monoamines and their metabolites in plasma and their correlations with clinical responses to haloperidol treatment.
    Nagaoka S; Iwamoto N; Arai H
    Biol Psychiatry; 1997 Apr; 41(8):857-64. PubMed ID: 9099412
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Behavioral vs biochemical prediction of clinical stability following haloperidol withdrawal in schizophrenia.
    van Kammen DP; Kelley ME; Gurklis JA; Gilbertson MW; Yao JK; Peters JL
    Arch Gen Psychiatry; 1995 Aug; 52(8):673-8. PubMed ID: 7543265
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effects of clozapine on plasma catecholamines and relation to treatment response in schizophrenia: a within-subject comparison with haloperidol.
    Brown AS; Gewirtz G; Harkavy-Friedman J; Cooper T; Brébion G; Amador XF; Malaspina D; Gorman JM
    Neuropsychopharmacology; 1997 Nov; 17(5):317-25. PubMed ID: 9348547
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cerebrospinal fluid and plasma monoamine metabolites and their relation to psychosis. Implications for regional brain dysfunction in schizophrenia.
    Pickar D; Breier A; Hsiao JK; Doran AR; Wolkowitz OM; Pato CN; Konicki PE; Potter WZ
    Arch Gen Psychiatry; 1990 Jul; 47(7):641-8. PubMed ID: 1694425
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Longitudinal changes in symptoms and plasma homovanillic acid levels in chronically medicated schizophrenic patients.
    Suzuki E; Kanba S; Nibuya M; Adachi S; Sekiya U; Shintani F; Kinoshita N; Yagi G; Asai M
    Biol Psychiatry; 1994 Nov; 36(10):654-61. PubMed ID: 7880934
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Noradrenergic activity and prediction of psychotic relapse following haloperidol withdrawal in schizophrenia.
    van Kammen DP; Agren H; Yao JK; O'Connor DT; Gurklis J; Peters JL
    Am J Psychiatry; 1994 Mar; 151(3):379-84. PubMed ID: 7509126
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pharmacoclinical correlations in schizophrenic patients treated with haloperidol decanoate: clinical evaluations, concentrations of plasma and red blood cell haloperidol and its reduced metabolite, and plasma homovanillic acid.
    Aymard N; Viala A; Stein I; Caroli F
    Prog Neuropsychopharmacol Biol Psychiatry; 1995 Nov; 19(7):1119-35. PubMed ID: 8787036
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Erythrocyte ketone reductase activity, total plasma haloperidol and acute psychoses].
    Dutoit D; Thomas P; Leroux JM; Vaiga G; Pommery J; Cottencin O; Erb F; Goudemand M
    Encephale; 1995; 21(6):417-24. PubMed ID: 8674466
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Plasma catecholamine metabolites and early response to haloperidol.
    Bowers MB; Swigar ME; Jatlow PI; Goicoechea N
    J Clin Psychiatry; 1984 Jun; 45(6):248-51. PubMed ID: 6725216
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Double blind comparative study of remoxipride and haloperidol in acute schizophrenic patients.
    Den Boer JA; Ravelli DP; Huisman J; Ohrvik J; Verhoeven WM; Westenberg HG
    Psychopharmacology (Berl); 1990; 102(1):76-84. PubMed ID: 1975448
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.